IMM.LSE ImmuPharma PLC

Healthcare Pharmaceuticals London Exchange
0.0352 GBX
Close of Nov 4, 2026
3.02 11.50
Market cap
GBX 22.0M
P/E
-
P/B
11.37x
ROE
-774.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IMM.LSE undervalued?

Graham number

The Graham number of ImmuPharma PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ImmuPharma PLC fundamental analysis

No fundamental analysis for ImmuPharma PLC yet.

ImmuPharma PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ImmuPharma PLC

ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocr…

Full company profile